Vertex Pharmaceuticals
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 2 months.
- Recent price momentum is +8.6% on average (3-month/1-year).
- Main-fund capital flow has been a net inflow over the last 45 sessions.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 02:27 UTC
Data coverage: 6 of 6 factors. Missing data is not a zero score.
Valuation F
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 33.1x | Better than 19% |
| Forward P/E | 34.1x | Better than 14% |
| Price / Sales | 10.5x | Better than 10% |
| P/E vs own 5-yr range | 99th pctl | Better than 3% |
Growth B-
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 10.4% | Better than 65% |
| Net income CAGR (3Y) | 6.0% | Better than 52% |
| Free cash flow CAGR (3Y) | -6.6% | Better than 31% |
Profitability A+
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 86.2% | Better than 94% |
| Operating margin | 37.9% | Better than 94% |
| Net margin | 32.9% | Better than 92% |
| Return on equity | 22.5% | Better than 81% |
| Return on invested capital | 18.3% | Better than 87% |
Momentum A-
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -6.0% | Better than 60% |
| 6-month return | 18.5% | Better than 81% |
| 12-month return (ex latest month) | 22.8% | Better than 62% |
| Distance below 52-week high | 9.4% | Better than 85% |
Financial Health A-
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 2.9x | Better than 72% |
| Debt to assets | 7.9% | Better than 73% |
| Interest coverage | 350.1x | Better than 97% |
| Free cash flow / net income | 80.8% | Better than 26% |
Analyst View B
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 95.2% | Better than 77% |
| Upside to average target | 21.1% | Better than 35% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 520.66
- Open
- 529.94
- Day range
- 513.80 - 531.37
- Avg price
- 519.15
- Volume
- 1.77M
- Turnover
- 917.82M
- Turnover ratei
- 0.70%
- Volume ratioi
- 1.43
- Amplitudei
- 3.38%
- 52-week rangei
- 412.27 - 568.67
Valuation
- P/Ei
- 33.62
- P/E (TTM)i
- 33.14
- P/Bi
- 6.25
- EPSi
- 15.32
- Book value / shi
- 82.46
- Net profit
- 3.88B
- Net assets
- 20.91B
Share structure
- Market cap
- 130.58B
- Float capi
- 130.19B
- Shares out
- 253.54M
- Float sharesi
- 252.79M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 1970-01-01
9.4% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
+5.74M net over the window
Short interest
- Shares short
- 4.81M
- % of floati
- 1.90%
- Days to coveri
- 3.38
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Vertex Pharmaceuticals (VRTX)?
Vertex Pharmaceuticals last traded at 515.02. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Vertex Pharmaceuticals's market cap?
About 130.58B.
What is the P/E ratio of Vertex Pharmaceuticals?
The trailing twelve-month P/E is 33.14. The Valuation tab shows it against the stock's own five-year range.
Does Vertex Pharmaceuticals pay a dividend?
Vertex Pharmaceuticals does not currently pay a regular dividend.
Is Vertex Pharmaceuticals a buy according to analysts?
The consensus of 21 analysts is a Buy rating, with an average 12-month price target of 623.65, which implies 21.1% upside from the current price. This is not investment advice.
What is Vertex Pharmaceuticals's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Vertex Pharmaceuticals a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 20:02:21 · For reference only, not investment advice and not tailored to your situation.
Vertex Pharmaceuticals discussion 0 comments